TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01343290
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
Study: NCT01384240
Drug: Proflavine Hemisulfate
Normalized name: Proflavine hemisulfate
DrugBank: Proflavine (DB01123)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
Study: NCT03692013
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
Study: NCT00661778
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study: NCT00661778
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study: NCT00661778
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study: NCT00553618
Drug: Proleukin and Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks.
Study: NCT01227980
Drug: Pexacerfont
Normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
Study: NCT00263874
Drug: UK-500,001
DrugBank: UK-500001 (DB12837)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01304849
Drug: Escalated BEACOPP
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm
Study: NCT01573598
Drug: Vilazodone
Normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilazodone, 20 mg per day, oral administration
Study: NCT01573598
Drug: Vilazodone
Normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilazodone, 40 mg once per day, oral administration
Study: NCT00005961
Drug: O6-benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005961
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02398240
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
Study: NCT02398240
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
Study: NCT02425449
Drug: Succinylcholine
Normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
Study: NCT02398240
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Days: 2 and 16 Dose: 375 mg/m2/dose.
Study: NCT04575493
Drug: Ciprofloxacin 500 mg
Normalized name: ciprofloxacin 500 MG
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Being a standard drug as antibiotic and will be used in Control group.
Study: NCT00486759
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study: NCT00486759
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab was administered at a dose of 375 mg/m\^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study: NCT00486759
Drug: CHOP
Normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide was administered at a dose of 750 mg/m\^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m\^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m\^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
Study: NCT00498914
Drug: YM155
Normalized name: Sepantronium bromide
DrugBank: Sepantronium (DB17062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion
Study: NCT01866306
Drug: LABA
Normalized name: Malabar Nut Leaf
DrugBank: Labafenogene marselecobac (DB17618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthmatic participants were treated with LABA as part of their standard of care
Study: NCT00329368
Drug: EC17 (Folate-FITC)
Normalized name: EC17 (Folate-FITC)
DrugBank: EC-17 (DB12559)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
Study: NCT00329368
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
Study: NCT00329368
Drug: Interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
Study: NCT01718366
Drug: Deferasirox, Vitamin D and Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
Study: NCT03884127
Drug: Ezetimibe 10mg
Normalized name: EZETIMIBE 10MG TAB
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
Study: NCT03884127
Drug: Orlistat 120 MG
Normalized name: orlistat 120 MG
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
Study: NCT04779892
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg/vial
Study: NCT03521037
Drug: Rucaparib camsylate
Normalized name: Rucaparib camsylate
DrugBank: Rucaparib (DB12332)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
Study: NCT04441112
Drug: Triamcinolone Intraarticular Injection
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injections will be given under ultrasound guidance with one of two possible medications.
Study: NCT00198549
Drug: Vitrase (ovine hyaluronidase) Lyophilized
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00033449
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00033449
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03999515
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03999515
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03999515
Drug: Erdafitinib
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01217944
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.5 mg ranibizumab intravitreal injection
Study: NCT01217944
Drug: Verteporfin PDT
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin (6 mg/m2) intravenous infusion
Study: NCT01217944
Drug: Sham Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empty vial to mimic the intravitreal injection
Study: NCT01217944
Drug: Sham verteporfin PDT
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
Study: NCT03647657
Drug: 177Lu-PP-F11N
Normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient
Study: NCT00726648
Drug: CDP323
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg capsules, 100mg bid for 4 weeks
Study: NCT00726648
Drug: CDP323
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg capsules, 500mg bid for 4 weeks
Study: NCT00726648
Drug: CDP323
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg capsules, 1000mg bid for 4 weeks
Study: NCT00726648
Drug: CDP323
Normalized name: CDP323
DrugBank: CDP323 (DB05092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg capsules, 1000mg daily for 4 weeks
Study: NCT02123849
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03965494
Drug: BGB 324 (before surgery)
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth either BEFORE therapeutic conventional surgery
Study: NCT03965494
Drug: BGB 324 (after surgery)
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth either AFTER therapeutic conventional surgery
Study: NCT02405156
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02405156
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04486651
Drug: Irinotecan Hydrochloride Injection
Normalized name: Irinotecan Hydrochloride Injection
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 160 mg/m² administered as IV infusion on Day 1 of each 14-day cycle.
Study: NCT04486651
Drug: HX008
Normalized name: Immunoglobulin g4 (252-theronine,306-proline,432-alanine), anti-(human programmed cell death 1) (human-mus musculus monoclonal hx008 .gamma.4-chain), disulfide with human-mus musculus monoclonal hx008 .kappa.-chain, dimer
DrugBank: Pucotenlimab (DB17552)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle.
Study: NCT04292054
Drug: active intervention
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The antibiotic prophylaxis will be cefazolin 2 g, or piperacilline-tazobactam 4 g, powder for solution for injection diluted in 50mL of NaCl 0.9%, IV infusion on 30 minutes with syringe pump.
Study: NCT02635607
Drug: Follitropin Beta
Normalized name: Follitropin Beta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
Study: NCT02635607
Drug: Ganirelix
Normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
Study: NCT02635607
Drug: Ganirelix
Normalized name: Ganirelix
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels\>600 pg/ml; and (iii) serum LH levels\>10 IU/l.
Study: NCT02635607
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
Study: NCT00598208
Drug: corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
Study: NCT00598208
Drug: Follitropin beta injection
Normalized name: follitropin beta Injection
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
Study: NCT01134562
Drug: Etelcalcetide
Normalized name: Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
Study: NCT00314054
Drug: HCV-796
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV-796 1000mg single dose
Study: NCT03458546
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
Study: NCT02378714
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
Study: NCT02084875
Drug: tofacitinib modified-release (MR) formulation
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
Study: NCT02525796
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
Study: NCT00888108
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
Study: NCT00140088
Drug: ALGRX 3268
Normalized name: ALGRX 1207
DrugBank: ALGRX 1207 (DB06482)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03656094
Drug: Pembrolizumab plus chemotherapy
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab plus chemotherapy
Study: NCT00773708
Drug: raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
Study: NCT02338245
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib 1250mg QD
Study: NCT01199783
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion (6 mg/kg/bodyweight) once daily
Study: NCT01199783
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
Study: NCT00506727
Drug: Mixed amphetamine salts (ADDERALL XR)
Normalized name: Amphetamine Mixed Salts Extended-Release Capsules
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00506727
Drug: Atomoxetine hydrochloride
Normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01499134
Drug: nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
Study: NCT01745367
Drug: Tivozanib Hydrochloride
Normalized name: tivozanib hydrochloride
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01745367
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01499134
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
Study: NCT00944333
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300-600 loading dose 75 mg/die for 6 months
Study: NCT00944333
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300-600 loading dose 75 mg/die for 12 months
Study: NCT04675944
Drug: treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 mg (1 extended-release tablet), oral route
Study: NCT02084875
Drug: tofacitinib modified-release (MR) formulation
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
Study: NCT04480827
Drug: Aramchol free acid tablet 600mg, single dose
DrugBank: Aramchol (DB11860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aramchol free acid tablet 600mg, single dose
Study: NCT04480827
Drug: Aramchol free acid tablet 300mg, bid
DrugBank: Aramchol (DB11860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aramchol acid tablet 300mg, bid for 12 days
Study: NCT02712658
Drug: Terbutaline
Normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
Study: NCT02890368
Drug: TTI-621 Monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages.